The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

EHA 2021 | QoL benefits of jaktinib for myelofibrosis patients

Name: QoL benefits of jaktinib for myelofibrosis patients
Uploaded: 2021-06-01T00:00:00Z
Duration: 1 min 8 s
Description: Jie Jin, MD, PhD, Zhejiang Medical University, Hangzhou, China, discussess the benefits of jaktinib treatment for patients with myelofibrosis, higlighting improvements in quality of life (QoL). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Jie Jin • 1 Jun 2021

EHA 2021

Anemias Myelofibrosis Myeloproliferative Neoplasms Jaktinib

Jie Jin, MD, PhD, Zhejiang Medical University, Hangzhou, China, discussess the benefits of jaktinib treatment for patients with myelofibrosis, higlighting improvements in quality of life (QoL). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.